{"name":"Gazda, Thomas D., M.D., PC","slug":"gazda-thomas-d-m-d-pc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Abilify Maintena","genericName":"Abilify Maintena","slug":"abilify-maintena","indication":"Schizophrenia (maintenance treatment)","status":"marketed"}]}],"pipeline":[{"name":"Abilify Maintena","genericName":"Abilify Maintena","slug":"abilify-maintena","phase":"marketed","mechanism":"Abilify Maintena is a long-acting intramuscular injection of aripiprazole that acts as a dopamine D2 receptor partial agonist to treat schizophrenia and bipolar disorder.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment of acute manic and mixed episodes)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}